{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:58:03Z","timestamp":1790351883557,"version":"4.1.0"},"reference-count":59,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T00:00:00Z","timestamp":1655769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1128\/ASMCopyrightv2"},{"start":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T00:00:00Z","timestamp":1655769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2012-1511"],"award-info":[{"award-number":["2012-1511"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002805","name":"Carl Tryggers Stiftelse f\u00f6r Vetenskaplig Forskning","doi-asserted-by":"publisher","award":["CTS16:395"],"award-info":[{"award-number":["CTS16:395"]}],"id":[{"id":"10.13039\/501100002805","id-type":"DOI","asserted-by":"publisher"}]},{"name":"\u00c5ke Wibergs Stiftelse"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2022,6,21]]},"abstract":"<jats:p>\u03b2-Lactam antibiotics are the first choice for the treatment of most bacterial infections. However, the increased prevalence of \u03b2-lactamases, in particular extended-spectrum \u03b2-lactamases, in pathogenic bacteria has severely limited the possibility of using \u03b2-lactam treatments.<\/jats:p>","DOI":"10.1128\/aac.00290-22","type":"journal-article","created":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T13:00:54Z","timestamp":1654174854000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":25,"title":["Evolutionary Trajectories toward High-Level \u03b2-Lactam\/\u03b2-Lactamase Inhibitor Resistance in the Presence of Multiple \u03b2-Lactamases"],"prefix":"10.1128","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4211-5696","authenticated-orcid":true,"given":"Fredrika","family":"Rajer","sequence":"first","affiliation":[{"name":"Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Allander","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0060-005X","authenticated-orcid":true,"given":"Philip A.","family":"Karlsson","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7382-9782","authenticated-orcid":true,"given":"Linus","family":"Sandegren","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-019-0159-8"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra041359"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlab092"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00047-19"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2007.01854.x"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2018.00016"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00117-13"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10080995"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00037-09"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.1.1.109"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mib.2010.09.006"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41429-020-0291-8"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2019.1660772"},{"key":"e_1_3_3_15_2","volume-title":"2020 antibacterial agents in clinical and preclinical development: an overview and analysis.","author":"World Health Organization","year":"2021","unstructured":"World Health Organization. 2021. 2020 antibacterial agents in clinical and preclinical development: an overview and analysis. World Health Organization, Geneva, Switzerland. https:\/\/www.who.int\/publications-detail-redirect\/9789240021303. Accessed 26 October 2021."},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41557-021-00831-x"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18668-2"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.00833"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx179"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.11.2547"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00583-18"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02097-16"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(87)91180-9"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/27.5.569"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.10.2059"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.757833"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0463.2008.00922.x"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr405"},{"key":"e_1_3_3_29_2","volume-title":"Infectious Diseases Society of America guidance on the treatment of antimicrobial resistant Gram-negative infections.","author":"Tamma PD","year":"2020","unstructured":"Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. 2020. Infectious Diseases Society of America guidance on the treatment of antimicrobial resistant Gram-negative infections. Infectious Diseases Society of America, Arlington, VA. https:\/\/www.idsociety.org\/practice-guideline\/amr-guidance\/. Accessed 26 October 2021."},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix034"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2021.11.025"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)70950-8"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir790"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1159\/000238765"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.172"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04146-14"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01612-17"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00178-11"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv475"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1042\/bj2760269"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0056926"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2018.00756"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01060-07"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00019-15"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/24.1.57"},{"key":"e_1_3_3_46_2","first-page":"598","article-title":"Prospective randomized study of piperacillin\/tazobactam therapy of surgically treated intra-abdominal infection. The Piperacillin\/Tazobactam Intra-Abdominal Infection Study Group","volume":"59","author":"Polk HC","year":"1993","unstructured":"Polk HC, Jr, Fink MP, Laverdiere M, Wilson SE, Garber GE, Barie PS, Hebert JC, Cheadle WG. 1993. Prospective randomized study of piperacillin\/tazobactam therapy of surgically treated intra-abdominal infection. The Piperacillin\/Tazobactam Intra-Abdominal Infection Study Group. Am Surg 59:598\u2013605.","journal-title":"Am Surg"},{"key":"e_1_3_3_47_2","first-page":"255","article-title":"Piperacillin\/tazobactam versus imipenem\/cilastatin in the treatment of intra-abdominal infections","volume":"176","author":"Niinikoski J","year":"1993","unstructured":"Niinikoski J, Havia T, Alhava E, P\u00e4\u00e4kk\u00f6nen M, Miettinen P, Kivilaakso E, Haapiainen R, Matikainen M, Laitinen S. 1993. Piperacillin\/tazobactam versus imipenem\/cilastatin in the treatment of intra-abdominal infections. Surg Gynecol Obstet 176:255\u2013261.","journal-title":"Surg Gynecol Obstet"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0902-x"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00797-10"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.5.1085"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro2174"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1128\/mSphere.00024-19"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00357-18"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02340-13"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw248"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1093\/molbev\/msu111"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.03552-21"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-018-0342-0"},{"key":"e_1_3_3_59_2","unstructured":"European Committee on Antimicrobial Susceptibility Testing. 2021. Breakpoint tables for interpretation of MICs and zone diameters version 11.0. https:\/\/eucast.org\/clinical_breakpoints\/. Accessed 26 October 2021."},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1128\/jb.177.14.4121-4130.1995"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00290-22","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00290-22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T14:50:23Z","timestamp":1655823023000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.00290-22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,21]]},"references-count":59,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6,21]]}},"alternative-id":["10.1128\/aac.00290-22"],"URL":"https:\/\/doi.org\/10.1128\/aac.00290-22","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,21]]},"assertion":[{"value":"2022-02-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00290-22"}}